Skip to main content
Premium Trial:

Request an Annual Quote

Tripos Shares Lose Ground Gained on Pfizer Extension

NEW YORK, Nov. 18 (GenomeWeb News) - Shares in Tripos lost almost all the ground they gained since Monday, when the company said it had extended a multimillion-dollar software license agreement with Pfizer.


Shares in the St. Louis bioinformatics company were down 9.23 percent at $4.92 in mid-afternoon trading after starting the day at $.5.36. On Monday, the stock climbed 15 percent to close at $5.25 after the Pfizer news jolted investors. The shares closed at $4.80 the day before the announcement.


The two companies initially announced a wide area network partnership in January 2001 that Pfizer employ a "broad array" of Tripos' drug-discovery software tools, including the SYBYL and UNITY programs.

Details of the extended agreement were not disclosed.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.